1. After a recent dose adjustment, dependent ankle swelling developed; weight, lung examination and jugular venous pressure remain unchanged.最近調整劑量後，出現姿勢性踝部水腫；體重、肺部檢查和頸靜脈壓保持不變。
2. Fatigue begins after a recent dose adjustment; ECG shows sinus rate 46/min, whereas BP and hemoglobin remain near baseline.最近調整劑量後開始感到疲勞；心電圖顯示竇性心率為46次/分，而血壓和血紅蛋白接近基準值。
3. A persistent nonproductive cough began several weeks after this regimen began; chest imaging, temperature and oxygenation are unchanged.在此治療方案開始數週後，出現持續性非生產性咳嗽；胸部影像、體溫和血氧飽和度均未改變。
4. New lightheadedness follows an increase in rate-control therapy; the PR interval lengthens and intermittent second-degree AV block appears.增加心率控制治療後出現新的頭暈；PR間期延長並出現間歇性二度房室傳導阻滯。
5. Potassium rises to 5.7 mEq/L (3.5-5.0) several weeks after treatment begins; repeat nonhemolyzed sampling confirms it, with no supplements or salt substitutes.治療開始數週後，血鉀升至5.7 mEq/L (3.5-5.0)；重複非溶血性採樣證實此結果，且未服用補充劑或代鹽。
6. Gum enlargement emerges over several months despite regular dental care; the client has no anticonvulsant or immunosuppressant exposure.儘管定期進行牙齒護理，牙齦增生仍持續數月；個案沒有接觸抗癲癇藥物或免疫抑制劑。
7. Painless tongue swelling develops while taking this regimen without hives or an allergen exposure; the airway is immediately assessed.在服用此治療方案期間出現無痛性舌頭腫脹，沒有蕁麻疹或過敏原接觸史；立即評估氣道。